Integrated microarray for identifying the hub mRNAs and constructed miRNA-mRNA network in coronary in-stent restenosis.

Linghong Song, Yufei Feng, Feng Tian, Xiaoang Liu, Shan Jin, Chengyan Wang, Wuyue Tang, Juncang Duan, Na Guo, Xihua Shen, Jianming Hu, Hong Zou, Wenyi Gu, Kejian Liu, Lijuan Pang

Journal: Physiological genomics 2022;54(10):371-379

PMID: 35968900

Abstract

As a major complication after percutaneous coronary intervention (PCI) in patients who suffer from coronary artery disease, in-stent restenosis (ISR) poses a significant challenge for clinical management. A miRNA-mRNA regulatory network of ISR can be constructed to better reveal the occurrence of ISR. The relevant data set from the Gene Expression Omnibus (GEO) database was downloaded, and 284 differentially expressed miRNAs (DE-miRNAs) and 849 differentially expressed mRNAs (DE-mRNAs) were identified. As predicted by online tools, 65 final functional genes (FmRNAs) were overlapping DE-mRNAs and DE-miRNAs target genes. In the biological process (BP) terms of gene ontology (GO) functional analysis, the FmRNAs were mainly enriched in the cellular response to peptide, epithelial cell proliferation, and response to peptide hormone. In the Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, the FmRNAs were mainly enriched in breast cancer, endocrine resistance, and Cushing syndrome. Jun proto-oncogene, activator protein-1 (AP-1) transcription factor subunit (), insulin-like growth factor 1 receptor (), member oncogene family (), specificity protein 1 (), protein tyrosine phosphatase nonreceptor type 1 (), DDB1 and CUL4 associated factor 10 (), retinoblastoma-binding protein 5 (), and eukaryotic initiation factor 4A-I () were hub genes in the protein-protein interaction network (PPI network). The miRNA-mRNA network containing DE-miRNAs and hub genes was built. Hsa-miR-139-5p-, hsa-miR-324-5p- axis pairs were found in the miRNA-mRNA network, which could promote ISR development. The aforementioned results indicate that the miRNA-mRNA network constructed in ISR has a regulatory role in the development of ISR and may provide new approaches for clinical treatment and experimental development.

Address: NHC Key Laboratory of Prevention and Treatment of Central Asia High Incidence Diseases (First Affiliated Hospital, School of Medicine, Shihezi University); Department of Pathology and Key Laboratory for Xinjiang Endemic and Ethnic Diseases, Shihezi University School of Medicine, Shihezi, People's Republic of China.; Department of Neurology, The First Affiliated Hospital, Shihezi University School of Medicine, Shihezi, People's Republic of China.; Shihezi University School of Pharmacy, Shihezi, People's Republic of China.; Department of Cardiology, Jinhua Municipal Central Hospital, Jinhua, People's Republic of China.; Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Saint Lucia, Queensland, Australia.; Department of Cardiology, The First Affiliated Hospital, Shihezi University School of Medicine, Shihezi, People's Republic of China.; Department of Pathology, Central People's Hospital of Zhanjiang and Zhanjiang Central Hospital, Guangdong Medical University, Zhanjiang, People's Republic of China.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.